Home › Funds › Atle Fund Management AB › SYRE
Atle Fund Management AB position in SYRE
Spyre Therapeutics Inc · Health Care
Atle Fund Management AB reported holding 44,243 shares of SYRE (Spyre Therapeutics Inc) in its Q3 2026 13F filing — a position valued at US$3.9M, representing 1.05% of its reported portfolio and ranking #30 among its reported holdings. Atle Fund Management AB has disclosed SYRE holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How Atle Fund Management AB's SYRE position evolved
Atle Fund Management AB first disclosed a stake in SYRE in Q1 2026 at 62,735 shares (US$3.5M). The position peaked in Q2 2026 at 57,030 shares, worth US$5.1M. Across 3 filings, Atle Fund Management AB increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 44,243 shares valued at US$3.9M — a reduction of -12,787 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 62.73K | $3.49M | New |
| Q2 2026 | 57.03K | $5.06M | Reduce |
| Q3 2026 | 44.24K | $3.94M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SYRE and 13F data
SYRE (Spyre Therapeutics Inc) is a Health Care company. 71 other funds we track also report a position in SYRE — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$377.5M), Paradigm Biocapital Advisors LP (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SYRE
- PERCEPTIVE ADVISORS LLC 4.32M sh · $383.48M · Q2 2026
- RTW INVESTMENTS, LP 4.25M sh · $377.49M · Q2 2026
- Paradigm Biocapital Advisors LP 3.84M sh · $340.98M · Q2 2026
- Venrock Adviser, LLC 2.99M sh · $265.05M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 2.80M sh · $248.51M · Q2 2026
- TCG Crossover Management, LLC 1.90M sh · $168.73M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.89M sh · $167.99M · Q2 2026
- Remedium Capital Partners, LLC 1.46M sh · $129.99M · Q2 2026
- Affinity Asset Advisors, LLC 1.28M sh · $113.56M · Q2 2026
- BRAIDWELL LP 879.47K sh · $78.08M · Q2 2026
- Siren, L.L.C. 868.60K sh · $77.33M · Q3 2026
- Commodore Capital LP 846.79K sh · $75.18M · Q2 2026
More on Atle Fund Management AB
FAQ
How long has Atle Fund Management AB held SYRE?
Atle Fund Management AB has disclosed SYRE holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Atle Fund Management AB's current position in SYRE?
As of Q3 2026, Atle Fund Management AB holds 44.24K shares of SYRE (Spyre Therapeutics Inc), valued at $3.94M, representing 1.05% of its reported portfolio and ranking #30.
Has Atle Fund Management AB been buying or selling SYRE?
In the latest 13F filing (Q3 2026), Atle Fund Management AB reduced its position in SYRE. The position peaked in Q2 2026 at 57.03K shares.
Which other funds hold SYRE?
Other major institutional holders of SYRE include PERCEPTIVE ADVISORS LLC, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 71 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.